ライフサイエンスコーパス: high-dose chemotherapy

1 acute leukaemia patients and those receiving high dose chemotherapy.

2 plus ifosfamide plus cisplatin preceded the high-dose chemotherapy.

3 e, but cannot be cured with conventional and high-dose chemotherapy.

4 cer patients from myelosuppression caused by high-dose chemotherapy.

5 or the bone marrow of 45 patients undergoing high-dose chemotherapy.

6 famide program, and six experienced CR after high-dose chemotherapy.

7 hs were attributable to the toxic effects of high-dose chemotherapy.

8 factor was administered after each cycle of high-dose chemotherapy.

9 ocytopenia, and anemia in patients receiving high-dose chemotherapy.

10 or eliminate the period of neutropenia after high-dose chemotherapy.

11 patients treated with either conventional or high-dose chemotherapy.

12 n bioreactors for 12 days, and infused after high-dose chemotherapy.

13 s effect was seen only in patients receiving high-dose chemotherapy.

14 e myeloma, including those who relapse after high-dose chemotherapy.

15 and accelerate hematopoietic recovery after high-dose chemotherapy.

16 malignancies that are currently treated with high-dose chemotherapy.

17 herapy, and, if they responded to treatment, high-dose chemotherapy.

18 marrow transplantation in patients receiving high-dose chemotherapy.

19 y mediastinal localization on the outcome of high-dose chemotherapy.

20 nd inferior responses to both induction- and high-dose chemotherapy.

21 is a complete response prior to or following high-dose chemotherapy.

22 total body irradiation (TBI) and multiagent, high-dose chemotherapy.

23 ic progenitor cells and reconstitution after high-dose chemotherapy.

24 ble subset of patients seems to benefit from high-dose chemotherapy.

25 on of the blood-brain barrier and the use of high-dose chemotherapy.

26 e conditioned with total body irradiation or high-dose chemotherapy.

27 udy of patients with breast cancer receiving high-dose chemotherapy, adjunct electroacupuncture was m

28 All patients were then treated with high-dose chemotherapy alone and observed for outcome.

29 ancy outcome among patients who had received high-dose chemotherapy alone or with total-body irradiat

30 Second- and third-line programs, including high-dose chemotherapy, also have curative potential.

31 d the liver or bone marrow were treated with high-dose chemotherapy and allogeneic PBPC transplantati

32 ntensive, involved-field radiotherapy before high-dose chemotherapy and ASCR, which was incorporated

33 of the earliest trials pioneering the use of high-dose chemotherapy and autologous bone marrow transp

34 Recipients of high-dose chemotherapy and autologous HCT (auto-HCT) inc

35 iastinum can achieve prolonged PFS following high-dose chemotherapy and autologous hematopoietic cell

36 e 1/2 study in lymphopenic individuals after high-dose chemotherapy and autologous hematopoietic stem

37 The addition of high-dose chemotherapy and autologous hematopoietic stem

38 High-dose chemotherapy and autologous hematopoietic stem

39 d cisplatin 75 mg/m(2) on day 1)-followed by high-dose chemotherapy and autologous HSCT in responders

40 Twenty-eight patients were given high-dose chemotherapy and autologous PBPCs plus culture

41 Cytopenia after high-dose chemotherapy and autologous stem cell reinfusi

42 High-dose chemotherapy and autologous stem cell transpla

43 iple myeloma cells in clinical samples after high-dose chemotherapy and autologous stem cell transpla

44 idates for aggressive salvage treatment with high-dose chemotherapy and autologous stem cell transpla

45 We compared second-line therapy with high-dose chemotherapy and autologous stem cell transpla

46 High-dose chemotherapy and autologous stem-cell transpla

47 and vomiting (CINV) for patients undergoing high-dose chemotherapy and autologous stem-cell transpla

48 d as maintenance treatment immediately after high-dose chemotherapy and autologous stem-cell transpla

49 udy was performed to evaluate the outcome of high-dose chemotherapy and autologous transplantation in

50 formulations to support patients undergoing high-dose chemotherapy and BMT are needed.

51 ressive non-Hodgkin lymphoma (NHL) following high-dose chemotherapy and CD34+-selected hematopoietic

52 Intensive management with primary high-dose chemotherapy and concurrent periocular carbopl

53 ogous stem cell transplantation (ASCT) after high-dose chemotherapy and followed by prolonged mainten

54 eral blood stem cells (PBSCs) mobilized with high-dose chemotherapy and hematopoietic growth factors

55 related mortality both in patients receiving high-dose chemotherapy and in those receiving moderately

56 final 3 days of cytokine therapy and, after high-dose chemotherapy and infusion of PBPCs, patients r

57 the severe immunodeficiency associated with high-dose chemotherapy and led to the induction of clini

58 patients with poor-prognosis lymphomas with high-dose chemotherapy and marrow or peripheral stem-cel

59 homas often fail salvage therapies including high-dose chemotherapy and mono-antigen-specific T-cell

60 High-dose chemotherapy and multimodality treatment seeme

61 The patient had a complete response to high-dose chemotherapy and no major acute complications.

62 BMT patients receive high-dose chemotherapy and often radiation, as well.

63 melphalan should thus be considered standard high-dose chemotherapy and ongoing randomised studies wi

64 ) to patients with breast cancer who undergo high-dose chemotherapy and PBPC transplantation was inve

65 T cells in breast cancer patients undergoing high-dose chemotherapy and peripheral blood stem cell tr

66 o intensify consolidation with triple-tandem high-dose chemotherapy and peripheral-blood stem-cell re

67 herapeutic strategies in patients undergoing high-dose chemotherapy and PSCT.

68 for AL amyloidosis involves choosing between high-dose chemotherapy and stem cell transplant or borte

69 rly 300 patients who had treatment combining high-dose chemotherapy and stem cell transplantation at

70 teria organs, followed in 6 months by either high-dose chemotherapy and stem cell transplantation for

71 The combination of high-dose chemotherapy and stem cell transplantation is

72 The remaining seven received high-dose chemotherapy and stem-cell infusion.

73 ed CAF alone and those who received CAF plus high-dose chemotherapy and stem-cell transplantation.

74 her progress is being reported on the use of high-dose chemotherapy and stem-cell transplants, althou

75 anti-CD20 therapy), were not candidates for high-dose chemotherapy and subsequent autologous stem-ce

76 story of myelodysplastic syndrome, underwent high-dose chemotherapy and total body irradiation prior

77 Oral mucositis is a common toxicity of high-dose chemotherapy and upper mantle head and neck ra

78 been viewed as an unavoidable consequence of high-dose chemotherapy and/or radiation.

79 py (fractionated total-body irradiation plus high-dose chemotherapy) and after autologous hematopoiet

80 Fifty of the 53 patients commenced high-dose chemotherapy, and 49 patients completed all fo

81 ent of the patients had AML or MDS requiring high-dose chemotherapy, and 93% of them were in the firs

82 tage and advanced epithelial ovarian cancer, high-dose chemotherapy, and biologic and gene therapy.

83 ea under the curve >/= 4 mg/mL per minute or high-dose chemotherapy, and for pediatric patients who r

84 his patient population that progressed after high-dose chemotherapy, and had not received prior pacli

85 sporine, total body irradiation, infections, high-dose chemotherapy, and recurrent malignancies.

86 py regimens, new trials exploring multicycle high-dose chemotherapy, and the development of prognosti

87 zed trials was not significantly improved by high-dose chemotherapy; any benefit from high doses was

88 e, and active, the use of multiple cycles of high-dose chemotherapy as front-line treatment remains e

89 High-dose chemotherapy as initial salvage chemotherapy a

90 otal of 56 consecutive patients treated with high-dose chemotherapy as part of this program.

91 spite new treatments and protocols including high doses chemotherapy associated with autologous stem

92 pite new treatments and protocols, including high-dose chemotherapy associated with autologous stem c

93 ve disease (VOD) is a common complication of high-dose chemotherapy associated with bone marrow trans

94 undred eighty-four patients received salvage high-dose chemotherapy at Indiana University (Indianapol

95 The role of salvage treatments and high-dose chemotherapy at relapse is not clear.

96 cell rescue was given after the last dose of high-dose chemotherapy, at least 24 h after melphalan in

97 intensification proceeded to consolidation (high-dose chemotherapy/auto-HCT per protocol).

98 a plasma-cell neoplasm that is treated with high-dose chemotherapy, autologous stem cell transplant

99 reated, measurable MM, who were eligible for high-dose chemotherapy-autologous stem-cell transplantat

100 sufficient to be effective as an adjunct to high-dose chemotherapies before stem cell transplantatio

101 cell transplantation (HCT), patients receive high-dose chemotherapy before transplantation and experi

102 ase who suffer from T-cell suppression after high-dose chemotherapy but are not deficient in NK cells

103 tly activated intergroup randomized study of high-dose chemotherapy compared with conventional dose c

104 L may display an increased susceptibility to high-dose chemotherapy compared with other types of B-ce

105 gave 173 patients two consecutive courses of high-dose chemotherapy consisting of 700 mg of carboplat

106 nts with advanced breast cancer treated with high-dose chemotherapy, consisting of cisplatin 250 mg/m

107 risk-adapted CSI followed by four cycles of high-dose chemotherapy (cyclophosphamide, cisplatin, and

108 urrent triple antiemetic pharmacotherapy and high-dose chemotherapy (cyclophosphamide, cisplatin, and

109 followed 45 consecutive women who underwent high-dose chemotherapy (cyclophosphamide/cisplatin/BCNU)

110 ms of the study were to determine 1) whether high-dose chemotherapy decreases concentrations of major

111 protect mice, but not cancer cells, against high-dose chemotherapy [differential stress resistance (

112 We use this framework to show how high-dose chemotherapy engenders opposing evolutionary p

113 ed with marker-dependent, early-intervention high-dose chemotherapy experienced longer survival (P =

114 emotherapy, the responding patients received high-dose chemotherapy followed by ASCT.

115 have shown the feasibility of administering high-dose chemotherapy followed by autologous bone marro

116 ase can be effectively treated or cured with high-dose chemotherapy followed by autologous haematopoi

117 t cancer are the most frequent recipients of high-dose chemotherapy followed by autologous hematopoie

118 chemotherapy, 14 patients were treated with high-dose chemotherapy followed by autologous stem-cell

119 Twelve patients were treated with high-dose chemotherapy followed by autologous stem-cell

120 High-intensity treatments, such as high-dose chemotherapy followed by haematopoietic stem c

121 High-dose chemotherapy followed by hematopoietic stem ce

122 Twenty-four patients received high-dose chemotherapy followed by infusion of the cultu

123 F) in 29 breast cancer patients treated with high-dose chemotherapy followed by PBPC reinfusion.

124 All patients underwent the same high-dose chemotherapy followed by reinfusion of PBCs.

125 f patients treated with sequential cycles of high-dose chemotherapy, followed by autologous PBPC infu

126 High-dose chemotherapy, followed by hematopoietic stem c

127 ceiving chemotherapy for acute leukaemia and high dose chemotherapy for solid tumours.

128 Controversy has surrounded the use of high-dose chemotherapy for breast cancer for more than a

129 authors review the main research results of high-dose chemotherapy for breast cancer in 2002 to 2003

130 he number of transfusions required following high-dose chemotherapy for breast cancer.

131 s treated uniformly in prospective trials of high-dose chemotherapy for four to nine positive axillar

132 ologous recipients hospitalized after recent high-dose chemotherapy for multiple myeloma.

133 chemotherapy should help clarify the role of high-dose chemotherapy for the treatment of this disease

134 /m(2) (5 mCi/m(2)) in patients who had prior high-dose chemotherapy (group 2), and at 0.370 GBq/m(2)

135 The immunosuppression provided by high-dose chemotherapy has been studied to address treat

136 High-dose chemotherapy has long been advocated as a mean

137 Early results of high-dose chemotherapy have been released, and the role

138 Patients with myeloma who relapse after high-dose chemotherapy have few therapeutic options.

139 Although surgery, radiation and high-dose chemotherapy have led to increased survival, m

140 = 68), or amyloidosis (n = 2), treated with high-dose chemotherapy (HDC) and ASCT without transfusio

141 luated the outcomes of patients who received high-dose chemotherapy (HDC) and autologous hematopoieti

142 ective study to determine the feasibility of high-dose chemotherapy (HDC) and autologous stem-cell re

143 The controversy surrounding high-dose chemotherapy (HDC) for breast cancer seems to

144 andomized study reported by Bezwoda et al of high-dose chemotherapy (HDC) for treatment of metastatic

145 and platelet recovery for patients receiving high-dose chemotherapy (HDC) supported with peripheral-b

146 t conventional-dose chemotherapy or from the high-dose chemotherapy (HDC) used for the transplant pro

147 Adjuvant high-dose chemotherapy (HDC) with autologous hematopoiet

148 ed adjuvant chemotherapy regimen followed by high-dose chemotherapy (HDC) with autologous hematopoiet

149 fulness of a treatment regimen that included high-dose chemotherapy (HDC) with autologous stem-cell r

150 High-dose chemotherapy (HDC) with autologous stem-cell t

151 High-dose chemotherapy (HDC) with peripheral-blood proge

152 women with advanced breast cancer undergoing high-dose chemotherapy (HDC).

153 combination with interleukin-2 (IL-2) after high-dose chemotherapy (HDC)/stem-cell rescue (SCR).

154 ow of patients with breast cancer undergoing high-dose chemotherapy (HDCT) and autologous bone marrow

155 t survival outcomes of patients treated with high-dose chemotherapy (HDCT) and peripheral-blood stem-

156 To investigate the role of high-dose chemotherapy (HDCT) as first-line treatment in

157 prognostic variables for patients undergoing high-dose chemotherapy (HDCT) as salvage modality for ge

158 Most of the data about high-dose chemotherapy (HDCT) for metastatic breast canc

159 the current role and future perspectives of high-dose chemotherapy (HDCT) in the management of advan

160 is conventional-dose chemotherapy (CDCT) or high-dose chemotherapy (HDCT).

161 dose-dense approach consolidated by up-front high-dose chemotherapy (HDT) and autologous stem-cell tr

162 tumor were treated with one or two cycles of high-dose chemotherapy (HDT) followed by autologous HSCR

163 High-dose chemotherapy (HDT) plus autologous stem cell t

164 o of our center's programs that incorporated high-dose chemotherapy (high-dose carboplatin plus etopo

165 e survival advantage is apparent in favor of high-dose chemotherapy in both high-risk primary and met

166 th the 62% 5-year survival rate after tandem high-dose chemotherapy in first-line salvage of metastat

167 venetoclax in combination with standard and high-dose chemotherapy in paediatric patients with relap

168 omparing conventional-dose chemotherapy with high-dose chemotherapy in patients in the early stages o

169 the preferred means of stem cell support for high-dose chemotherapy in recent years.

170 r the randomized studies evaluating adjuvant high-dose chemotherapy in the early stages of breast can

171 s of disease, and chemotherapy, particularly high-dose chemotherapy in the first-line and salvage set

172 The role of high-dose chemotherapy in the management of women with b

173 phamide, mitoxantrone, etoposide regimen for high-dose chemotherapy in women with high-risk primary b

174 High-dose chemotherapy increasingly is being employed to

175 High-dose chemotherapy increasingly is being used for th

176 High dose chemotherapy induced the phosphorylation of p5

177 atched sibling donors are unavailable unless high-dose chemotherapy is given.

178 emission with induction therapy with AFM and high-dose chemotherapy is increased for hormone receptor

179 High-dose chemotherapy is increasingly being employed to

180 High-dose chemotherapy is increasingly being employed to

181 High-dose chemotherapy is increasingly utilized for the

182 values can alter the outcome from one where high-dose chemotherapy is optimal to one where using the

183 The role of high-dose chemotherapy is still debated.

184 ity in patients with low tumor burdens after high-dose chemotherapy, limited use of low-dose oral eto

185 There is a hint that high-dose chemotherapy may play a role in relapsed patie

186 Radiation and high-dose chemotherapy may render women with cancer prem

187 t undermines predictions that limited use of high-dose chemotherapy might be minimally leukemogenic,

188 The effect of high-dose chemotherapy on overall survival was not stati

189 x vivo expansion of stem cells to be used in high-dose chemotherapy or gene therapy.

190 hat oncogenic translocations occurring after high-dose chemotherapy or radiation could be prevented b

191 In the HIV-negative setting, high-dose chemotherapy or stem cell transplantation is a

192 After high-dose chemotherapy, patients who had peripheral-bloo

193 Salvage high-dose chemotherapy plus a stem-cell transplant was r

194 Salvage high-dose chemotherapy plus a stem-cell transplant was u

195 ntenance chemotherapy in conventional doses, high-dose chemotherapy plus autologous stem-cell transpl

196 High-dose chemotherapy plus autologous stem-cell transpl

197 ree and overall survival have been seen with high-dose chemotherapy plus autologous stem-cell transpl

198 o progression of the disease (9.6 months for high-dose chemotherapy plus hematopoietic stem cells and

199 these, 110 patients were assigned to receive high-dose chemotherapy plus hematopoietic stem cells and

200 cted a randomized trial in which we compared high-dose chemotherapy plus hematopoietic stem-cell resc

201 r tumors are potentially curable by means of high-dose chemotherapy plus hematopoietic stem-cell resc

202 minimal toxicity and reduced use of salvage high-dose chemotherapy plus stem-cell transplant.

203 High-dose chemotherapy poses considerable challenges to

204 Treatment includes high-dose chemotherapy preceded by surgical resection an

205 osfamide, and cisplatin, single agents, or a high-dose chemotherapy program.

206 ipheral blood progenitor cells (PBPCs) after high-dose chemotherapy rapidly restores multilineage hem

207 refractory myeloma (76 with a relapse after high-dose chemotherapy) received oral thalidomide as a s

208 of which were for patients who received the high-dose-chemotherapy regimen.

209 rent or poor-prognosis CNS malignancies with high-dose chemotherapy regimens followed by autologous m

210 The use of high-dose chemotherapy regimens is limited by the severi

211 cluded an open-label randomised arm in which high-dose chemotherapy regimens were compared.

212 of tumor cells in the autologous graft, new high-dose chemotherapy regimens, new trials exploring mu

213 arrow toxicity, the limiting factor for most high-dose chemotherapy regimens.

214 rincipal element of supportive care for many high-dose chemotherapy regimens.

215 eled antibodies, total-body irradiation, and high-dose chemotherapy remain disease free.

216 High-dose chemotherapy remains a valid research strategy

217 to 36 months with conventional therapy, but high-dose chemotherapy resulted in better outcomes in a

218 ials have suggested a survival advantage for high-dose chemotherapy, several randomised studies have

219 The most relevant alternatives to WBRT are high-dose chemotherapy supported by autologous stem cell

220 mbining surgery, craniospinal radiation, and high-dose chemotherapy, that often cause disabling neuro

221 carbazine) followed by a novel consolidation high-dose chemotherapy (thiotepa, busulfan, cyclophospha

222 llowed by whole-brain radiotherapy (WBRT) or high-dose chemotherapy (thiotepa-busulfan-cyclophosphami

223 sease-free survival among patients receiving high-dose chemotherapy, those undergoing autologous bone

224 od stem-cell transplantation (referred to as high-dose chemotherapy) to women with metastatic disease

225 ous bone marrow transplantation as part of a high-dose chemotherapy treatment for advanced cancer wer

226 potential for delivery of rapidly sequenced high-dose chemotherapy treatments rescued with autologou

227 uated the effect of treosulfan and melphalan high-dose chemotherapy (TreoMel-HDT) followed by reinfus

228 High-dose chemotherapy using diverse regimens with hemat

229 High-dose chemotherapy using high-dose etoposide as ther

230 High-dose chemotherapy was associated with significant m

231 ved chemotherapy; multimodality treatment or high-dose chemotherapy was not associated with statistic

232 Attempts to achieve cure with high-dose chemotherapy were conducted in the 1990s, with

233 Partial responders then received immediate high-dose chemotherapy, whereas those who achieved compl

234 These advances were: introduction of high dose chemotherapy, which appears to be superior to

235 Patients were ineligible for high-dose chemotherapy, which would put them at risk for

236 may affect the outcome of patients receiving high dose chemotherapy with autologous transplantation o

237 ators have suggested that consolidation with high dose chemotherapy with or without radiation therapy

238 High-dose chemotherapy with a combination of vincristine

239 High-dose chemotherapy with ABMT is promising in patient

240 Meta-analysis of the use of high-dose chemotherapy with autologous hematopoetic stem

241 The impact of high-dose chemotherapy with autologous hematopoietic cel

242 ncer is currently the primary indication for high-dose chemotherapy with autologous hematopoietic pro

243 High-dose chemotherapy with autologous hematopoietic ste

244 Meta-analysis of data on the use of high-dose chemotherapy with autologous hematopoietic ste

245 High-dose chemotherapy with autologous marrow or stem ce

246 a better chance of long-term remission with high-dose chemotherapy with autologous stem cell rescue

247 filtration rate, and intention to proceed to high-dose chemotherapy with autologous stem cell transpl

248 resulted from clinical trials incorporating high-dose chemotherapy with autologous stem cell transpl

249 2-3 cycles of chemoimmunotherapy followed by high-dose chemotherapy with autologous stem cell transpl

250 High-dose chemotherapy with autologous stem cell transpl

251 High-dose chemotherapy with autologous stem cell transpl

252 to evaluate the effect of busulfan-melphalan high-dose chemotherapy with autologous stem-cell rescue

253 ich patients are most likely to benefit from high-dose chemotherapy with autologous stem-cell rescue.

254 sed multiple myeloma and were ineligible for high-dose chemotherapy with autologous stem-cell transpl

255 sed multiple myeloma who were ineligible for high-dose chemotherapy with autologous stem-cell transpl

256 status score of 0-2, and were ineligible for high-dose chemotherapy with autologous stem-cell transpl

257 ocol-defined chemoimmunotherapy, followed by high-dose chemotherapy with autologous stem-cell transpl

258 who were not eligible for or had experienced high-dose chemotherapy with autologous stem-cell transpl

259 ree cycles of chemoimmunotherapy followed by high-dose chemotherapy with autologous stem-cell transpl

260 Purpose The benefit of high-dose chemotherapy with autologous stem-cell transpl

261 High-dose chemotherapy with autologous stem-cell transpl

262 l agents, conventional cytotoxic agents, and high-dose chemotherapy with autotransplantation (modalit

263 High-dose chemotherapy with autotransplantation, which h

264 Substantial interest in supporting high-dose chemotherapy with bone marrow or autologous he

265 There may be a role for high-dose chemotherapy with bone marrow rescue in relaps

266 We aimed to assess event-free survival after high-dose chemotherapy with busulfan and melphalan compa

267 include the first randomized trial comparing high-dose chemotherapy with conventional-dose chemothera

268 r the same adjuvant chemotherapy followed by high-dose chemotherapy with cyclophosphamide and thiotep

269 The patients underwent high-dose chemotherapy with cyclophosphamide, carboplati

270 ntial economic benefit in patients receiving high-dose chemotherapy with either bone marrow or periph

271 High-dose chemotherapy with haemopoietic stem-cell rescu

272 High-dose chemotherapy with hematopoietic progenitor cel

273 sion were randomized to immediate or delayed high-dose chemotherapy with hematopoietic stem-cell supp

274 re groups of patients who might benefit from high-dose chemotherapy with hematopoietic support.

275 age, 1.8 years; range, 0.4 to 7.9) received high-dose chemotherapy with or without irradiation and B

276 nge, 0.9 to 3.2 years) with MPS I H received high-dose chemotherapy with or without radiation followe

277 Before high-dose chemotherapy with or without stem cell rescue

278 agent chemotherapy, followed by 3 courses of high-dose chemotherapy with peripheral blood stem cell r

279 High-dose chemotherapy with peripheral blood stem cell t

280 dation of his second remission, he underwent high-dose chemotherapy with peripheral blood stem cell t

281 apy, for patients with disseminated disease, high-dose chemotherapy with peripheral blood transplanta

282 lvage chemotherapy with tandem transplant of high-dose chemotherapy with peripheral stem cell rescue.

283 The efficacy of high-dose chemotherapy with progenitor-cell rescue for w

284 Numerous randomized trials have compared high-dose chemotherapy with standard-dose chemotherapy i

285 The role of chemotherapy, radiation, and high-dose chemotherapy with stem cell rescue in the mana

286 Conclusive evidence for the efficacy of high-dose chemotherapy with stem cell rescue is lacking

287 ed relapse; if surgery is not feasible, then high-dose chemotherapy with stem cell transplant in an e

288 ons, including reduced-dose radiotherapy and high-dose chemotherapy with stem-cell rescue, aiming at

289 older than 12 months varied; most receiving high-dose chemotherapy with stem-cell rescue.

290 Administering four consecutive cycles of high-dose chemotherapy with stem-cell support after surg

291 High-dose chemotherapy with stem-cell support produced p

292 90 average risk) followed by four cycles of high-dose chemotherapy with stem-cell support.

293 ol into conventional protocols or the use of high-dose chemotherapy with stem-cell transplants.

294 atin combination chemotherapy and subsequent high-dose chemotherapy with tandem transplantation.

295 or without second-look surgery proceeded to high-dose chemotherapy with thiotepa and etoposide and a

296 In patients given high-dose chemotherapy, with or without radiation, for t

297 Most patients received high-dose chemotherapy without radiation for pretranspla

298 High-dose chemotherapy without stem cell rescue has been

299 ssibility of decreasing disease activity but high-dose chemotherapy without stem cell rescue having a

300 cells concomitant with the administration of high-dose chemotherapy would reduce the duration of abso